Echinocandin Dosing for Invasive Candidiasis
For adults with invasive candidiasis, use the following echinocandin dosing regimens: anidulafungin 200 mg loading dose then 100 mg daily, caspofungin 70 mg loading dose then 50 mg daily, or micafungin 100 mg daily without a loading dose. 1, 2, 1
Standard Dosing Regimens
The three available echinocandins have distinct but equally effective dosing strategies:
Anidulafungin
- Loading dose: 200 mg IV on day 1
- Maintenance dose: 100 mg IV daily starting day 2
- No dose adjustment needed for hepatic or renal impairment 1, 2, 1
Caspofungin
- Loading dose: 70 mg IV on day 1
- Maintenance dose: 50 mg IV daily starting day 2
- Hepatic impairment adjustment: Reduce maintenance dose to 35 mg daily in patients with moderate hepatic insufficiency (Child-Pugh score 7-9) 1, 2, 1
Micafungin
- Standard dose: 100 mg IV daily (no loading dose required)
- No dose adjustment needed for hepatic or renal impairment 1, 2, 1
Key Clinical Considerations
All three echinocandins are recommended as first-line therapy for invasive candidiasis with strong evidence 1. The 2016 IDSA guidelines provide the highest quality evidence supporting these regimens, with strong recommendations based on high-quality evidence for echinocandins as initial therapy 1.
When to Choose Each Agent
The choice between echinocandins can be guided by:
- Caspofungin requires dose reduction in moderate hepatic impairment, making it less convenient in liver disease 1, 2
- Anidulafungin has no drug interactions and undergoes chemical degradation rather than hepatic metabolism, making it ideal for patients on multiple medications 3, 4
- Micafungin requires no loading dose, simplifying initiation, though some practitioners use higher loading doses (150-200 mg) off-label 5
Special Populations Requiring Dose Adjustments
Critically ill patients, those with altered volume of distribution, or patients on extracorporeal circuits may require higher doses or therapeutic drug monitoring 6, 7. The global 2025 ECMM guideline emphasizes that standard dosing may be insufficient in:
- Morbidly obese patients
- Patients receiving ECMO or CRRT
- Those with severe hypoalbuminemia
- Pediatric populations (dose by body surface area, not included here as question specifies adults) 6, 7
Common Pitfalls to Avoid
Do not reduce caspofungin dose in mild hepatic impairment - only moderate to severe impairment requires adjustment 1, 8
Do not skip the loading dose for anidulafungin or caspofungin - this delays achievement of therapeutic concentrations 1, 4
Do not assume all echinocandins require loading doses - micafungin reaches steady state without one 1
Do not use reduced doses for renal impairment - none of the echinocandins require renal dose adjustment 3, 8
Duration and De-escalation
Continue echinocandin therapy until clinical stability is achieved, typically allowing step-down to fluconazole after 5 days in stable patients with susceptible isolates 9, 10. The 2016 IDSA guidelines recommend transition to fluconazole for patients who are clinically stable with isolates likely susceptible to fluconazole 1.
The most recent 2025 global guideline emphasizes earlier IV-to-oral step-down in stable non-neutropenic patients with appropriate source control 6, 10.